What is the current stock price of Eisai Co., Ltd. (ESAIY)?

As of the latest market data, Eisai Co., Ltd. (ESAIY) is trading at $7.92. The stock has seen a gain of 2.72% today.

Does Eisai Co., Ltd. (ESAIY) pay a dividend?

Based on current data, Eisai Co., Ltd. does not have a confirmed active dividend policy.

What is the market cap of Eisai Co., Ltd.?

The current market capitalization of Eisai Co., Ltd. (ESAIY) is approximately unavailable.

ESAIY

Eisai Co., Ltd.·Healthcare

7.92

2.724%(+0.21)

Close Price

Last Updated: — ET

52W L: $6.1852W H: $9.22

ESAIY NEWS

prnewswire.com

Apr 9

Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting

NUTLEY, N.J., April 9, 2026 /PRNewswire/ -- Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 2026 American Academy of Neurology (AAN) Annual Meeting from April 18-22 in Chicago and online.

prnewswire.com

Mar 26

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global leading research-based pharmaceutical company working

seekingalpha.com

Feb 9

Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript

Company Profile

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

11,067

IPO Date

2023-02-02

Beta

-0.10

Websitewww.eisai.co.jp↗